Thinking about cancer or dealing with cancer risk can be scary or overwhelming, but we believe that receiving information and resources is comforting, empowering, and lifesaving.
In the general population, prostate cancer is common. Men have about a 14% risk for developing the disease by age 80.
Men with BRCA mutations have a 15-25% lifetime risk for prostate cancer, which is much higher than average-risk men. In men with BRCA mutations, prostate cancers tend to occur at a younger age and may be more aggressive and life threatening than prostate cancer in men without mutations.
Other genes are believed to increase the risk for hereditary prostate cancer. If prostate cancer runs in your family, it is important to consult with a genetics specialist to determine risk and management options.
Although some organizations recommend against routine prostate cancer screening in the general population, screening may be more beneficial for men with BRCA mutations because of their prostate cancer risk. Experts recommend a Prostate Specific Antigen (PSA) blood test and baseline digital rectal exam for all men with BRCA mutations, starting at age 40.
The IMPACT study is a prostate surveillance research study for men with a BRCA mutation.
If you have already been diagnosed with prostate cancer, speak with your doctor about tests that can determine if your prostate cancer is an aggressive form that may require additional treatment. Recent studies have found that about 10% of men with advanced (metastatic) prostate cancer have mutations in genes associated with hereditary breast and ovarian cancer including BRCA2, ATM, CHEK2, BRCA1, and others.